Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert delphi analysis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients : an expert delphi analysis. / Østergaard, Svetlana; Møldrup, C.

In: Public Health Genomics, Vol. 13, No. 7-8, 2010.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Østergaard, S & Møldrup, C 2010, 'Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert delphi analysis', Public Health Genomics, vol. 13, no. 7-8. https://doi.org/10.1159/000313467

APA

Østergaard, S., & Møldrup, C. (2010). Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert delphi analysis. Public Health Genomics, 13(7-8). https://doi.org/10.1159/000313467

Vancouver

Østergaard S, Møldrup C. Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert delphi analysis. Public Health Genomics. 2010;13(7-8). https://doi.org/10.1159/000313467

Author

Østergaard, Svetlana ; Møldrup, C. / Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients : an expert delphi analysis. In: Public Health Genomics. 2010 ; Vol. 13, No. 7-8.

Bibtex

@article{0635ebe0932e11df928f000ea68e967b,
title = "Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert delphi analysis",
abstract = "Objective: The aim of this study was to investigate experts' opinions regarding the extent to which the introduction of pretesting for polymorphism of serotonin transporter promoter region (5-HTTLPR) as a routine intervention in clinical practice would lead to better clinical outcomes for depression patients. Methods: Using an internet survey system, authors of clinical studies addressing the topic of association of 5-HTTLPR genotyping with antidepressant response were contacted to participate in a Delphi study. Results: Responses from 12 experts were used for the final analysis. According to the participants, the introduction of 5-HTTLPR genotyping will lead to 33.8, 48.2, 57.8, and 65.1{\%} of patients reaching remission at 1, 2, 3, and 6 months, respectively. Conclusions: According to experts, application of 5-HTTLPR pretreatment genotyping might influence remission; however, the estimated remission rates with genotyping at first sight do not appear to be superior to existing practice, i.e. without genotyping. It is anticipated that a combination of 5-HTTLPR testing with other genomic variables, which have yet to be determined, and compliance measurements can improve clinical outcomes in the future. At present, the introduction of 5-HTTLPR genotyping is expected to be used only in special situations.",
keywords = "The Faculty of Pharmaceutical Sciences",
author = "Svetlana {\O}stergaard and C M{\o}ldrup",
note = "Copyright {\circledC} 2010 S. Karger AG, Basel.",
year = "2010",
doi = "10.1159/000313467",
language = "English",
volume = "13",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S Karger AG",
number = "7-8",

}

RIS

TY - JOUR

T1 - Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients

T2 - an expert delphi analysis

AU - Østergaard, Svetlana

AU - Møldrup, C

N1 - Copyright © 2010 S. Karger AG, Basel.

PY - 2010

Y1 - 2010

N2 - Objective: The aim of this study was to investigate experts' opinions regarding the extent to which the introduction of pretesting for polymorphism of serotonin transporter promoter region (5-HTTLPR) as a routine intervention in clinical practice would lead to better clinical outcomes for depression patients. Methods: Using an internet survey system, authors of clinical studies addressing the topic of association of 5-HTTLPR genotyping with antidepressant response were contacted to participate in a Delphi study. Results: Responses from 12 experts were used for the final analysis. According to the participants, the introduction of 5-HTTLPR genotyping will lead to 33.8, 48.2, 57.8, and 65.1% of patients reaching remission at 1, 2, 3, and 6 months, respectively. Conclusions: According to experts, application of 5-HTTLPR pretreatment genotyping might influence remission; however, the estimated remission rates with genotyping at first sight do not appear to be superior to existing practice, i.e. without genotyping. It is anticipated that a combination of 5-HTTLPR testing with other genomic variables, which have yet to be determined, and compliance measurements can improve clinical outcomes in the future. At present, the introduction of 5-HTTLPR genotyping is expected to be used only in special situations.

AB - Objective: The aim of this study was to investigate experts' opinions regarding the extent to which the introduction of pretesting for polymorphism of serotonin transporter promoter region (5-HTTLPR) as a routine intervention in clinical practice would lead to better clinical outcomes for depression patients. Methods: Using an internet survey system, authors of clinical studies addressing the topic of association of 5-HTTLPR genotyping with antidepressant response were contacted to participate in a Delphi study. Results: Responses from 12 experts were used for the final analysis. According to the participants, the introduction of 5-HTTLPR genotyping will lead to 33.8, 48.2, 57.8, and 65.1% of patients reaching remission at 1, 2, 3, and 6 months, respectively. Conclusions: According to experts, application of 5-HTTLPR pretreatment genotyping might influence remission; however, the estimated remission rates with genotyping at first sight do not appear to be superior to existing practice, i.e. without genotyping. It is anticipated that a combination of 5-HTTLPR testing with other genomic variables, which have yet to be determined, and compliance measurements can improve clinical outcomes in the future. At present, the introduction of 5-HTTLPR genotyping is expected to be used only in special situations.

KW - The Faculty of Pharmaceutical Sciences

U2 - 10.1159/000313467

DO - 10.1159/000313467

M3 - Journal article

VL - 13

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 7-8

ER -

ID: 20920560